Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Hypothesis

Signaling pathway switch in breast cancer

Authors: Arnaud Guille, Max Chaffanet, Daniel Birnbaum

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Next generation sequencing studies have drawn the general landscape of breast cancers and identified hundreds of new, actual therapeutic targets. Two major signaling pathways seem to be altered in a vast proportion of breast cancers. The PI3 kinase/AKT pathway is activated and the JUN/MAPK pathway is repressed. Via the regulation of the cell cycle this metabolic switch impacts on the balance between self-renewal, proliferation and differentiation of the tumor-initiating cells
Appendix
Available only for authorised users
Literature
1.
The Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 2012, 490: 61-70. 10.1038/nature11412.PubMedCentralCrossRef
2.
Shah P, Roth A, Goya R, Oloumi A, Ha G, Zhao Y: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012, 486: 385-399.
3.
Banerji S, Cibulskis K, Rangel-Escareno K, Brown KK, Carter SL, Frederick AM: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012, 486: 405-409. 10.1038/nature11154.PubMedCentralCrossRefPubMed
4.
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW: Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012, 486: 353-360.PubMedCentralPubMed
5.
Birnbaum D, Sircoulomb F, Imbert J: A reason why the ERBB2 gene is amplified and not mutated in breast cancer. Cancer Cell Int. 2009, 9: 5-10.1186/1475-2867-9-5.PubMedCentralCrossRefPubMed
6.
Hynes N, MacDonald G: ErbB receptors and signaling pathways in cancer. Curr Op Cell Biol. 2009, 21: 177-184. 10.1016/j.ceb.2008.12.010.CrossRefPubMed
7.
Wu G, Feng X, Lincoln Stein L: A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 2010, 11: R53-10.1186/gb-2010-11-5-r53.PubMedCentralCrossRefPubMed
8.
Oxford KW, Scadden DT: Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet. 2008, 9: 115-127. 10.1038/nrg2269.CrossRef
9.
Burdon T, Smith A, Savatier P: Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol. 2002, 12: 432-438. 10.1016/S0962-8924(02)02352-8.CrossRefPubMed
10.
11.
Eijkelenboom A, Burgering BMT: FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol. 2013, 14: 83-97.CrossRefPubMed
12.
Grunt TW, Mariani GL: Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets. 2013, 13: 188-204. 10.2174/1568009611313020008.CrossRefPubMed
13.
Eisinger F, Sobol H, Birnbaum D: Hypothesis: more mutations to cure cancer?. Oncol Rep. 1999, 6: 1189-1190.PubMed
Metadata
Title
Signaling pathway switch in breast cancer
Authors
Arnaud Guille
Max Chaffanet
Daniel Birnbaum
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-66

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue

Primary research

Correlation between B7-H3 expression and matrix metalloproteinases 2 expression in pancreatic cancer

Primary research

Role of relaxin-2 in human primary osteosarcoma

Primary research

Overexpression of p65 attenuates celecoxib-induced cell death in MDA-MB-231 human breast cancer cell line

Primary research

Tumor cell response to bevacizumab single agent therapy in vitro

Primary research

Spindle and kinetochore associated complex subunit 1 regulates the proliferation of oral adenosquamous carcinoma CAL-27 cells in vitro

Review

The flavokawains: uprising medicinal chalcones
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits